acute megakaryoblastic leukemia

Syros squeaks out with $50M IPO to get POC data

Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes. Now, it has raised $50 million in an IPO to get proof-of-concept data.

Stacy Lawrence Jun 29, 2016 9:49pm